Comparative Pharmacology
Head-to-head clinical analysis: ALLERNAZE versus FAYOSIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERNAZE versus FAYOSIM.
ALLERNAZE vs FAYOSIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at histamine H1 receptors, preventing histamine-mediated symptoms such as itching, sneezing, and vasodilation.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
5 mg orally once daily at bedtime, maximum 10 mg per day.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. Clinical context: Allows for twice-daily dosing in allergic rhinitis; steady-state reached in 2-3 days.
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Primarily renal (70-80% as unchanged drug and metabolites), with approximately 5-10% biliary/fecal elimination.
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Category C
Category C
Antihistamine
Antihistamine